Revision of Ahmed glaucoma valve failed by incarcerated fibrovascular ingrowth
Session Details
Session Title: Presented Poster Session: Glaucoma and Imaging
Venue: Poster Village: Pod 3
First Author: : Y.Kim SOUTH KOREA
Co Author(s): : J. Park C. Yoo
Abstract Details
Purpose:
When we encounter a late failure of Ahmed glaucoma valve (AGV) implantation, we may consider the secondary AGV implantation or cyclophotocoagulation. However, revision of AGV can correct the problem in some cases. The purpose of our study was to report the efficacy of removing incarcerated fibrovascular membrane into the AGV.
Setting:
Korea University Guro Hospital
Methods:
We conducted a retrospective chart and video review of all patients who underwent revision of AGV (removal of the incarcerated fibrovascular membrane into the AGV) at Korea University Guro Hospital from January 2012 through January 2014. Data included glaucoma diagnosis, age at the revision, preoperative/postoperative intraocular pressure (IOP) and medications, and the time interval between the primary AGV implantation and the surgical removal of the fibrovascular membrane.
Results:
Four patients, two males and two females, with a mean age at fibrovascular ingrowth removal of 52.9 ± 10.2 years were identified. Before revision, blebs around AGV were flat in all 4 cases. Mean pre-revision IOP was 43.0 ± 15.0 mmHg (range 23 to 56) with 3.5 ± 0.6 medications. Mean time from the primary AGV implantation to fibrovascular ingrowth removal was 41.6 ± 11.8 months. The IOP and number of medications were significantly reduced to 16.8 ± 4.0 mmHg and 2.0 ± 1.2, respectively, at 6 months after removing the incarcerated fibrovascular membrane.
Conclusions:
When IOP increases after the AGV implantation during the late postoperative period, we may consider explore AGV and look into fibrovascular ingrowth. Surgical removal of the fibrovascular ingrowth can be effective at lowering IOP in eyes with failed AGV due to fibrovascular ingrowth.
Financial Disclosure:
NONE
